Public change history
Changes and corrections
Factual corrections and retractions are separated from routine editorial or source updates. Earlier public versions remain available rather than being silently erased.
Material record
Corrections and retractions
Factual errors, withdrawals, and retractions appear here separately from routine wording or source updates.
If one is published, the earlier version, reason, date, and supporting source will remain visible.
Version history
Editorial and source updates
These entries preserve wording changes or ordinary source-record updates. An entry here does not by itself mean the earlier version contained a factual error.
Bremelanotide profile · version 3
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
Version 3 supersedes public version 2.
Liraglutide profile · version 3
We added a product-name lookup term that the cited FDA label communication connects to liraglutide. The profile's status did not change.
Version 3 supersedes public version 2.
Semaglutide profile · version 3
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
Version 3 supersedes public version 2.
Tirzepatide profile · version 3
We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.
Version 3 supersedes public version 2.
BPC-157 profile · version 2
We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.
Version 2 supersedes public version 1.
GHK-Cu profile · version 2
We added FDA substance-identity aliases to improve search matching. The cited compounding-list status did not change.
Version 2 supersedes public version 1.
MOTS-c profile · version 2
We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.
Version 2 supersedes public version 1.
TB-500 profile · version 2
We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
Version 2 supersedes public version 1.
Abaloparatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Afamelanotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Amycretin profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Bremelanotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Cagrilintide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Dulaglutide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Elamipretide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Exenatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Glucagon profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Insulin glargine-aldy profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Lanreotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Leuprolide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Linaclotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Liraglutide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Lixisenatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Maridebart cafraglutide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Mazdutide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Octreotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Pemvidutide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Petrelintide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Plecanatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Pramlintide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Retatrutide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Semaglutide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Setmelanotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Survodutide profile · version 2
We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.
Version 2 supersedes public version 1.
Teriparatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Tesamorelin profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Tirzepatide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Vosoritide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
Ziconotide profile · version 2
We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.
Version 2 supersedes public version 1.
How version history works
PeptideScanner checks the cited record, preserves the earlier public version, and publishes a dated notice explaining the change. A factual correction identifies the error and supporting source; a routine update is labeled separately.
Reader reports
Reporting channel status
Representatives from GoodSir Labs publish and review PeptideScanner. PeptideScanner does not yet publish a dedicated reporting channel. A verified organization-level route will appear here before the site invites submissions; no personal contact details are exposed in the meantime.